A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Healthy Volunteer

Interventions

DRUG

ABBV-701

Subcutaneous

DRUG

Placebo

Subcutaneous

Trial Locations (1)

RECRUITING

Acpru /Id# 273354, Grayslake